Lead Product(s) : Vixotrigine
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy
Details : Phase 2 CONVEY study of vixotrigine (BIIB074), a non-opioid investigational oral pain drug being evaluated for the treatment of small fiber neuropathy (SFN).
Product Name : BIIB074
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 16, 2021
Lead Product(s) : Vixotrigine
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable